NO312290B1 - Farmasöytisk preparat inneholdende 4-oksobutansyrer, samt forbindelser som omfattes av disse - Google Patents
Farmasöytisk preparat inneholdende 4-oksobutansyrer, samt forbindelser som omfattes av disse Download PDFInfo
- Publication number
- NO312290B1 NO312290B1 NO19990707A NO990707A NO312290B1 NO 312290 B1 NO312290 B1 NO 312290B1 NO 19990707 A NO19990707 A NO 19990707A NO 990707 A NO990707 A NO 990707A NO 312290 B1 NO312290 B1 NO 312290B1
- Authority
- NO
- Norway
- Prior art keywords
- oxobutanoic acid
- benzyl
- phenyl
- acid
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 32
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical class OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- -1 methylenedioxy group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- QPORTTBGWVROJY-UHFFFAOYSA-N 2-benzyl-4-oxo-4-phenylbutanoic acid Chemical compound C=1C=CC=CC=1CC(C(=O)O)CC(=O)C1=CC=CC=C1 QPORTTBGWVROJY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- GVPCMJHFPQEBOL-UHFFFAOYSA-N 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid;2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid;2-(cyclohexylmethyl)-4-(4-methoxyphenyl)-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1CC(C(=O)O)CC(=O)C1=CC=C(F)C=C1.C1=CC(OC)=CC=C1C(=O)CC(C(O)=O)CC1CCCCC1.C1=CC(OC)=CC=C1C(=O)CC(C(O)=O)CC1=CC=CC=C1 GVPCMJHFPQEBOL-UHFFFAOYSA-N 0.000 claims 1
- OBDXDWVDQXGGOD-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)-2-benzyl-4-oxobutanoic acid;2-benzyl-4-cyclohexyl-4-oxobutanoic acid;4-oxo-2-(oxolan-2-ylmethyl)-4-phenylbutanoic acid Chemical compound C=1C=CC=CC=1C(=O)CC(C(=O)O)CC1CCCO1.C=1C=CC=CC=1CC(C(=O)O)CC(=O)C1CCCCC1.C=1C=C2OCOC2=CC=1C(=O)CC(C(=O)O)CC1=CC=CC=C1 OBDXDWVDQXGGOD-UHFFFAOYSA-N 0.000 claims 1
- MHCNHRLQVIIPIR-UHFFFAOYSA-N FC1=CC=C(C=C1)C(CC(C(=O)O)CC1=CC=C(C=C1)OC)=O.C(C1=CC=CC=C1)C(C(=O)O)CC(=O)C1=CC=C(C=C1)C.ClC1=CC=C(C=C1)CC(C(=O)O)CC(=O)C1=CC=C(C=C1)OC Chemical compound FC1=CC=C(C=C1)C(CC(C(=O)O)CC1=CC=C(C=C1)OC)=O.C(C1=CC=CC=C1)C(C(=O)O)CC(=O)C1=CC=C(C=C1)C.ClC1=CC=C(C=C1)CC(C(=O)O)CC(=O)C1=CC=C(C=C1)OC MHCNHRLQVIIPIR-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- DZRBTTWGDHUKDS-UHFFFAOYSA-N 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1CC(C(=O)O)CC(=O)C1=CC=C(F)C=C1 DZRBTTWGDHUKDS-UHFFFAOYSA-N 0.000 description 4
- TVLYZHRGSUXOQF-UHFFFAOYSA-N 2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)CC(C(O)=O)CC1=CC=CC=C1 TVLYZHRGSUXOQF-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- QIXYGJBDJCMKHU-UHFFFAOYSA-N diethyl 2-benzyl-2-[2-(4-methoxyphenyl)-2-oxoethyl]propanedioate Chemical compound C=1C=CC=CC=1CC(C(=O)OCC)(C(=O)OCC)CC(=O)C1=CC=C(OC)C=C1 QIXYGJBDJCMKHU-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- VOOXIDRRCBFFLQ-UHFFFAOYSA-N 2-(cyclohexylmethyl)-4-(4-methoxyphenyl)-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)CC(C(O)=O)CC1CCCCC1 VOOXIDRRCBFFLQ-UHFFFAOYSA-N 0.000 description 1
- NYCYMQAQDZTLJC-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-4-(4-methoxyphenyl)-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)CC(C(O)=O)CC1=CC=C(Cl)C=C1 NYCYMQAQDZTLJC-UHFFFAOYSA-N 0.000 description 1
- XQFUJCBHFJJCEZ-UHFFFAOYSA-N 2-benzyl-2-ethoxycarbonyl-4-(4-fluorophenyl)-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1CC(C(O)=O)(C(=O)OCC)CC(=O)C1=CC=C(F)C=C1 XQFUJCBHFJJCEZ-UHFFFAOYSA-N 0.000 description 1
- XJOAUHZBMKCWQW-UHFFFAOYSA-N 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid;2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1CC(C(=O)O)CC(=O)C1=CC=C(F)C=C1.C1=CC(OC)=CC=C1C(=O)CC(C(O)=O)CC1=CC=CC=C1 XJOAUHZBMKCWQW-UHFFFAOYSA-N 0.000 description 1
- STDPGSJNESFTQC-UHFFFAOYSA-N 2-benzyl-4-(4-methylphenyl)-4-oxobutanoic acid Chemical compound C1=CC(C)=CC=C1C(=O)CC(C(O)=O)CC1=CC=CC=C1 STDPGSJNESFTQC-UHFFFAOYSA-N 0.000 description 1
- YRNDGUSDBCARGC-UHFFFAOYSA-N 2-methoxyacetophenone Chemical compound COCC(=O)C1=CC=CC=C1 YRNDGUSDBCARGC-UHFFFAOYSA-N 0.000 description 1
- PMKQMSUQRFIWTD-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1CC(C(O)=O)CC(=O)C1=CC=C(F)C=C1 PMKQMSUQRFIWTD-UHFFFAOYSA-N 0.000 description 1
- DSZFVARAOPNLQT-UHFFFAOYSA-N 4-oxo-2-(oxolan-2-ylmethyl)-4-phenylbutanoic acid Chemical compound C=1C=CC=CC=1C(=O)CC(C(=O)O)CC1CCCO1 DSZFVARAOPNLQT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CEUKGEBPTAQSFJ-UHFFFAOYSA-N C(C1=CC=CC=C1)C(C(=O)O)CC(=O)C1CCCCC1.C(C1=CC=CC=C1)C(C(=O)O)CC(=O)C1=CC2=C(C=C1)OCO2 Chemical compound C(C1=CC=CC=C1)C(C(=O)O)CC(=O)C1CCCCC1.C(C1=CC=CC=C1)C(C(=O)O)CC(=O)C1=CC2=C(C=C1)OCO2 CEUKGEBPTAQSFJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000911 decarboxylating effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ICZLTZWATFXDLP-UHFFFAOYSA-N diethyl 2-benzylpropanedioate Chemical compound CCOC(=O)C(C(=O)OCC)CC1=CC=CC=C1 ICZLTZWATFXDLP-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000023187 negative regulation of glucagon secretion Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9610254A FR2752422B1 (fr) | 1996-08-16 | 1996-08-16 | Composition pharmaceutique contenant des acides 4-oxo-butanoiques |
| PCT/EP1997/004252 WO1998007681A1 (fr) | 1996-08-16 | 1997-08-05 | Compositions pharmaceutiques contenant des acides 4-oxo-butanoiques |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO990707D0 NO990707D0 (no) | 1999-02-15 |
| NO990707L NO990707L (no) | 1999-02-15 |
| NO312290B1 true NO312290B1 (no) | 2002-04-22 |
Family
ID=9495089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19990707A NO312290B1 (no) | 1996-08-16 | 1999-02-15 | Farmasöytisk preparat inneholdende 4-oksobutansyrer, samt forbindelser som omfattes av disse |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6143787A (xx) |
| EP (1) | EP0925273B1 (xx) |
| JP (1) | JP3105545B2 (xx) |
| KR (1) | KR100488430B1 (xx) |
| CN (1) | CN1082370C (xx) |
| AR (1) | AR009251A1 (xx) |
| AT (1) | ATE208364T1 (xx) |
| AU (1) | AU725440B2 (xx) |
| BR (1) | BR9711315A (xx) |
| CA (1) | CA2263348C (xx) |
| CY (1) | CY2298B1 (xx) |
| CZ (1) | CZ294165B6 (xx) |
| DE (1) | DE69708130T2 (xx) |
| DK (1) | DK0925273T3 (xx) |
| ES (1) | ES2166098T3 (xx) |
| FR (1) | FR2752422B1 (xx) |
| HK (1) | HK1021728A1 (xx) |
| HU (1) | HUP0004223A3 (xx) |
| ID (1) | ID17875A (xx) |
| NO (1) | NO312290B1 (xx) |
| PL (1) | PL187371B1 (xx) |
| PT (1) | PT925273E (xx) |
| RU (1) | RU2175966C2 (xx) |
| SI (1) | SI0925273T1 (xx) |
| SK (1) | SK283055B6 (xx) |
| TR (1) | TR199900329T2 (xx) |
| TW (1) | TW438764B (xx) |
| UA (1) | UA57031C2 (xx) |
| WO (1) | WO1998007681A1 (xx) |
| ZA (1) | ZA977327B (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04318852A (ja) * | 1991-04-18 | 1992-11-10 | Fujitsu Ltd | レジスト・パターン形成方法 |
| NZ530051A (en) | 2001-06-12 | 2006-12-22 | Wellstat Therapeutics Corp | Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders |
| FR2832633B1 (fr) * | 2001-11-28 | 2004-09-24 | Lipha | Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete |
| FR2832925B1 (fr) * | 2001-12-03 | 2006-07-14 | Lipha | Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation |
| FR2834214B1 (fr) * | 2001-12-28 | 2004-09-24 | Lipha | Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete |
| FR2834640B1 (fr) * | 2002-01-11 | 2004-09-24 | Lipha | Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete |
| EP1556085A4 (en) * | 2002-11-01 | 2012-08-22 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| WO2004041256A2 (en) * | 2002-11-08 | 2004-05-21 | Novo Nordisk A/S | Safe chemical uncouplers for the treatment of obesity |
| FR2849598B1 (fr) * | 2003-01-07 | 2006-09-22 | Merck Sante Sas | Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans |
| FR2849599B1 (fr) * | 2003-01-07 | 2006-12-29 | Merck Sante Sas | Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete |
| PT1633340E (pt) * | 2003-04-15 | 2011-02-22 | Wellstat Therapeutics Corp | Compostos para o tratamento de distúrbios metabólicos |
| US20100273872A1 (en) | 2007-12-03 | 2010-10-28 | Valerie Autier | Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250517A (en) * | 1987-10-06 | 1993-10-05 | Hoffmann-La Roche Inc. | Renin inhibiting compounds |
| DK523288A (da) * | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| CA1329680C (en) * | 1987-11-23 | 1994-05-17 | Harold Norris Weller, Iii | N-heterocyclic alcohol derivatives |
| US5055466A (en) * | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
-
1996
- 1996-08-16 FR FR9610254A patent/FR2752422B1/fr not_active Expired - Fee Related
-
1997
- 1997-05-08 UA UA99031301A patent/UA57031C2/uk unknown
- 1997-08-05 DE DE69708130T patent/DE69708130T2/de not_active Expired - Lifetime
- 1997-08-05 DK DK97936682T patent/DK0925273T3/da active
- 1997-08-05 JP JP10510330A patent/JP3105545B2/ja not_active Expired - Fee Related
- 1997-08-05 RU RU99105208/04A patent/RU2175966C2/ru not_active IP Right Cessation
- 1997-08-05 SK SK180-99A patent/SK283055B6/sk not_active IP Right Cessation
- 1997-08-05 KR KR10-1999-7001122A patent/KR100488430B1/ko not_active IP Right Cessation
- 1997-08-05 CZ CZ1999498A patent/CZ294165B6/cs not_active IP Right Cessation
- 1997-08-05 PT PT97936682T patent/PT925273E/pt unknown
- 1997-08-05 HU HU0004223A patent/HUP0004223A3/hu unknown
- 1997-08-05 EP EP97936682A patent/EP0925273B1/fr not_active Expired - Lifetime
- 1997-08-05 BR BR9711315A patent/BR9711315A/pt not_active IP Right Cessation
- 1997-08-05 US US09/230,849 patent/US6143787A/en not_active Expired - Fee Related
- 1997-08-05 AT AT97936682T patent/ATE208364T1/de not_active IP Right Cessation
- 1997-08-05 AU AU39422/97A patent/AU725440B2/en not_active Ceased
- 1997-08-05 CA CA002263348A patent/CA2263348C/en not_active Expired - Fee Related
- 1997-08-05 TR TR1999/00329T patent/TR199900329T2/xx unknown
- 1997-08-05 SI SI9730237T patent/SI0925273T1/xx unknown
- 1997-08-05 WO PCT/EP1997/004252 patent/WO1998007681A1/fr active IP Right Grant
- 1997-08-05 ES ES97936682T patent/ES2166098T3/es not_active Expired - Lifetime
- 1997-08-05 CN CN97197180A patent/CN1082370C/zh not_active Expired - Fee Related
- 1997-08-14 ID IDP972848A patent/ID17875A/id unknown
- 1997-08-14 ZA ZA9707327A patent/ZA977327B/xx unknown
- 1997-08-15 AR ARP970103720A patent/AR009251A1/es active IP Right Grant
- 1997-10-23 TW TW086115700A patent/TW438764B/zh active
-
1999
- 1999-02-12 PL PL97331645A patent/PL187371B1/pl not_active IP Right Cessation
- 1999-02-15 NO NO19990707A patent/NO312290B1/no not_active IP Right Cessation
-
2000
- 2000-01-31 HK HK00100582A patent/HK1021728A1/xx not_active IP Right Cessation
-
2002
- 2002-09-24 CY CY0200057A patent/CY2298B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI67369C (fi) | Foerfarande foer framstaellning av nya terapeutiskt aktiva derivat av 3,4-dehydroprolin | |
| NO312290B1 (no) | Farmasöytisk preparat inneholdende 4-oksobutansyrer, samt forbindelser som omfattes av disse | |
| US3383411A (en) | 4-alkanoylphenoxy-alkanoic acids | |
| IE53226B1 (en) | Enkephalinase enzyme inhibiting compounds | |
| SU976850A3 (ru) | Способ получени производных 5-замещенных @ -пиронов | |
| JPWO2008062830A1 (ja) | スピロキノン化合物及び医薬組成物 | |
| JP2004527547A (ja) | 抗凝血薬として用いるクマリン誘導体 | |
| US4134991A (en) | Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid | |
| IE49541B1 (en) | 4,5-dihydro-1-(3-mercapto-1-oxopropyl)-3-phenyl-1h-pyrazole-5-carboxylic acid and derivatives thereof | |
| US4659728A (en) | Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid | |
| US4055595A (en) | Substituted aryloxy-3,3,3-trifluoro-2-propionic acids, esters and salts thereof | |
| US4775691A (en) | 4H-benzo[4,5]cyclohepta[1,2-b]thiophene derivatives | |
| US3598861A (en) | 2-(5'-phenyl-m-terphenyl - 4 - yloxy) lower aliphatic monocarbocyclic acids and esters thereof | |
| US4599357A (en) | 1-mercaptoalkanoylindoline-2-carboxylic acids | |
| US3598860A (en) | 2 - (4 -(3',4' - diphenylcyclopentyl)-phenoxy) lower aliphatic monocarbocyclic acids and esters thereof | |
| US4237134A (en) | Derivatives of thiazolidinecarboxylic acids and related acids | |
| MXPA99001482A (en) | Pharmaceutical composition containing 4-oxo-butynic acids | |
| NO180085B (no) | Acylsulfonamido- og sulfonamidopyridin-2-karboksylsyreestere og deres anvendelse som legemidler | |
| NO133142B (xx) | ||
| US3598862A (en) | 2 - (4 - (3',5' - diphenylcyclohexyl) - phenoxy)lower aliphatic monocarbocylic acids and esters thereof | |
| US4628057A (en) | Tetrahydro-β-carboline derivatives and treatment of liver diseases | |
| IE67059B1 (en) | A process for the preparation of a 1,4-dihydropyridine derivative namely (-)-2-{[2-(aminoethoxy)ethoxy]methyl}-4-(2,3-dichlorophenyl)-3-ethoxy-carbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine and its salts | |
| NO852616L (no) | Fenylaminopropiofenon-derivater og fremgangsmaate til fremstilling derav. | |
| IL33813A (en) | Bornanocarboxamides and their salts,and their preparation | |
| PT88504B (pt) | Processo para a preparacao de haloalquil-tiazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |